secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001770787-23-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q1 revenue $134.3M (+17% YoY); net loss $50.7M; raises FY2023 guidance to $590-$610M
--------------------------------------------------------------------------------

- Revenue $134.3M (+17% YoY); spatial portfolio drove growth, Xenium in first full launch quarter.
- Net loss $50.7M vs $42.4M in prior year; operating loss $52.0M incl $42.1M stock-based comp.
- Gross margin 73% (down from 78%) due to product mix and inventory write-downs.
- Raised FY2023 revenue guidance to $590-610M (prev $580-600M); 14-18% growth.
- Cash and marketable securities $418.3M as of March 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/0001770787-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/txg-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001770787-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer